Skip to main content
68°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Rezolute Inc
(NQ:
RZLT
)
4.240
+0.020 (+0.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Rezolute Inc
< Previous
1
2
Next >
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
August 05, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
July 31, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
June 27, 2024
Additional $6.7M in funding resulting in approximately $67M in gross proceeds
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Inc. (NASDAQ: RZLT) Climbs to New 52-Week High
April 15, 2024
Via
Investor Brand Network
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
June 24, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
June 13, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 13, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
May 21, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
May 15, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
April 23, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
3 Stocks Insiders Are Buying That Analysts Love
March 26, 2024
Insiders are buying these stocks that analysts view as undervalued. Each has a potential catalyst in the works, and its shares could advance triple digits.
Via
MarketBeat
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
March 06, 2024
Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism)
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
February 13, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
January 24, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
January 23, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
December 13, 2023
Plans to report topline data mid-second quarter 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
November 24, 2023
Dallas, Texas--(Newsfile Corp. - November 24, 2023) - Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday...
Via
Newsfile
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
November 17, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports First Quarter Fiscal 2024 Results
November 13, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
October 17, 2023
PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
October 11, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
September 14, 2023
Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Participate in Upcoming Investor Conferences in September
September 06, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
June 27, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease
June 01, 2023
Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare...
Via
Newsfile
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
May 11, 2023
The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
March 23, 2023
RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
March 08, 2023
Conference call and webcast to be held on Wednesday, March 22 at 4:30 pm EDT
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
February 10, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.